

Solodyn - (45,65,90,115,135 mg; Tablet ER)

Generic Name	Minocycline Hydrochloride	Innovator	Medicis (Valeant)
Dosage	45,65,90,115,135 mg; Tablet ER	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	More Than 5
Indication	None		
Complexities	No		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Solodyn - (80mg, 105mg; Tablet ER)

Generic Name	Minocycline Hydrochloride	Innovator	Medicis (Valeant)
Dosage	80mg, 105mg; Tablet ER	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	Less Than 5
Indication	Indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Solodyn - (55mg; Tablet, Extended release)

Generic Name	Minocycline Hydrochloride	Innovator	Medicis (Valeant)
Dosage	55mg; Tablet, Extended release	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	None	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	Indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.